KOSDAQRetail & Consumer064090

InkredibleBuzz

₩798 0.00%2026-11-18 close
Market Cap
₩39.7B
Turnover
₩0
Volume
0 shares
Shares out.
49.7M
PER
—
PBR
0.7×
EPS
-₩283
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Loss-making pivot story; trading resumption is the key variable

InkredibleBuzz is shifting from luxury distribution toward healthcare and medical devices, but its disclosed results show an operating loss in each year from 2022 to 2025, and trading has been suspended since February 9, 2026.

  1. 1

    Disclosed 2025 revenue rose 58.1% year on year to KRW 7.21 billion, but the operating loss widened to KRW 6.08 billion.

  2. 2

    Net loss attributable to controlling shareholders was KRW 30.2 billion in 2025, reversing from a KRW 19 billion profit in 2024.

  3. 3

    Quarterly revenue has declined for four consecutive quarters from Q4 2025 through Q3 2026, reaching KRW 553 million in the latest quarter.

  4. 4

    Domestic regulatory approvals for Aminogum Gel and the injectable skin-barrier device Suneokos are the key variables for the healthcare pivot, and the hospital partner channel has been built.

  5. 5

    The review of the first half of 2026 ended with a disclaimer of opinion on both consolidated and standalone statements; the P/B ratio sits below 1x, while PER cannot be calculated because the last four quarters were net losses.

02

Business structure

InkredibleBuzz was listed on KOSDAQ in 2002 as a general wholesaler of goods, and its business was historically centered on fashion and sundry distribution and marketing.

The company says that since the second half of 2024 it has moved away from a luxury-distribution structure toward a portfolio centered on healthcare, medical devices and platforms.

The drinkable amino-acid product Nutracos Drinkable came under distribution rights acquired in February 2025, and the healthcare division accounted for 86% of revenue in the first quarter of 2025, the most recent segment share confirmed.

The company describes the Nutracos business as forming a stable revenue flow, while the beauty fintech platform Gangnam Oppa adds finance and advertising income to diversify revenue.

The two pillars of the medical device business are Aminogum Gel, a gel-form finished device used in hospitals for periodontal treatment, and Suneokos, an injectable device that delivers a skin-barrier rebuilding substance.

Both products are advancing through domestic regulatory approval, and Suneokos has completed TGA registration in Australia, securing a local distribution base.

The company has finished building a cooperative channel with hospitals and clinics, but profitability improvement has been delayed because the products must clear Ministry of Food and Drug Safety requirements.

Competitively, the model depends on distribution rights and channel access, so approval outcomes and hospital channel performance will determine competitiveness.

Trading in the shares has been suspended since February 9, 2026, and the company has named a substantive normalization of its business as the key condition for resuming trading.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2B-₩1.6B−77.4%
2025Q4₩1.7B-₩1.8B−103.5%
2026Q1₩1.4B-₩3B−207.2%
2026Q2₩600M-₩1.8B−288.9%
2026Q3₩600M-₩200M−37.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩29.4B-₩13.2B-₩15B−45.0%−404.5%133.1%
2023₩6.9B-₩600M-₩7B−8.2%−19.3%66.0%
2024₩4.6B-₩3.5B₩19B−77.5%19.7%3.1%
2025₩7.2B-₩6.1B-₩30.2B−84.3%−45.2%6.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 29.4 billion in 2022 to KRW 6.9 billion in 2023 (down 76.5% year on year) and KRW 4.56 billion in 2024 (down 33.9%), before rising to KRW 7.21 billion in 2025 (up 58.1%). Within 2022 to 2025, 2022 was the largest year and 2024 the smallest.

The operating loss was KRW 13.2 billion in 2022, KRW 569 million in 2023, KRW 3.54 billion in 2024 and KRW 6.08 billion in 2025, so the company recorded operating losses for four consecutive years from 2022 through 2025.

The operating margin was -45.0% in 2022, -8.2% in 2023, -77.5% in 2024 and -84.3% in 2025, the lowest of the period.

The company attributed the widening 2025 loss to higher revenue from its online business alongside rising payment commissions and advertising costs, and the preliminary annual results were announced on March 27, 2026.

Net loss attributable to controlling shareholders was KRW 15 billion in 2022, KRW 6.99 billion in 2023, a net profit of KRW 19 billion in 2024 that turned the result positive, and a net loss of KRW 30.2 billion in 2025 that turned it negative again.

In 2024 the operating loss and the profit attributable to controlling shareholders pointed in opposite directions, so non-operating items weighed heavily on that year's result.

At the end of 2025, total equity was KRW 66.8 billion, all of it attributable to controlling shareholders, total liabilities were KRW 4.16 billion, and the debt-to-equity ratio was 6.2%. Operating cash flow was -KRW 918 million in 2022, -KRW 10.5 billion in 2023, KRW 1.63 billion in 2024 and -KRW 11.3 billion in 2025.

Quarterly revenue went from KRW 2.01 billion in Q3 2025 to KRW 1.71 billion in Q4 2025, KRW 1.45 billion in Q1 2026, KRW 625 million in Q2 2026 and KRW 553 million in Q3 2026, a decline for four consecutive quarters, and Q3 2026 revenue was down 72.5% year on year.

The operating loss peaked at KRW 3 billion in Q1 2026 and narrowed to KRW 204 million in Q3 2026. Net loss attributable to controlling shareholders narrowed from KRW 6 billion in Q4 2025 to KRW 1.04 billion in Q3 2026, and the four quarters from Q4 2025 through Q3 2026 total KRW 14 billion.

Whether the narrowing loss on falling revenue reflects expense adjustment will be checked against the next annual report.

05

Industry analysis

The skin booster market, where the company has entered, is projected by one analysis to grow about 10% a year globally and reach roughly USD 2.1 billion by 2030. This is a market forecast and does not translate directly into revenue for the company.

The company said its legacy fashion and luxury distribution has been shrinking because of low profitability. Medical device products require Ministry of Food and Drug Safety product approval, so the speed of market entry depends on approval timing.

According to the company, unit sales of Nutracos Drinkable grew at an average of 40% a year over the three years from 2021. A 2025 press report noted that the Aminogum Gel business had not yet ramped up, and that revenue growth was attributed to the Nutracos distribution rights.

The company describes the decline in quarterly revenue in 2026 as part of normalizing past practices of artificial revenue expansion and short-term distribution-led operations. Whether weakness reflects the industry or the restructuring needs to be separated using quarterly revenue mix.

Compared with large retailers in the consumer distribution sector, the company's revenue base is small, so product approvals and channel access matter more than the industry cycle.

While trading is suspended, whether the listing is maintained and the conditions for resuming trading affect the share price independently of operating metrics.

06

Outlook

The company expects its business transition to take hold in 2026 and turnaround to become visible. It has said that a substantive normalization of the business and the resolution of legal disputes driven by specific stakeholders are important for resuming trading.

Aminogum Gel and the related amino product are advancing through domestic approval, and the company hopes they can become a sustainable revenue model built on repeat purchases. Suneokos is moving through the transition in Europe from the MDD framework to MDR, and has completed TGA registration in Australia.

The hospital partner channel is in place, but because revenue depends on Ministry of Food and Drug Safety approval, the timing of profitability improvement depends on the approval outcome.

The financial statements for the first half of 2026, covering the period from January 1 to June 30, received a disclaimer of opinion from the external auditor on both consolidated and standalone bases, with the review report received on August 14, 2026.

Trading has been suspended since February 9, 2026, and the suspension continues until a decision is made on whether the company is subject to a listing-eligibility substantive review.

The next periodic report is the 2026 annual report, and its full-year revenue, operating loss and audit opinion are the first disclosed checkpoints for whether the normalization is taking hold.

The largest shareholder group held 15.45% as of the last change dated January 22, 2026, and legal disputes over control could affect business plans and fundraising timing.

07

Valuation

PER
—
PBR
0.7×
ROE
-21.2%
EPS
-₩283
BPS
₩1,183
Dividend per share
₩0

Because the last four quarters were net losses, PER cannot be calculated. The price-to-book ratio is below 1x, meaning market capitalization is smaller than book equity.

Total equity fell from KRW 96.8 billion at the end of 2024 to KRW 66.8 billion at the end of 2025, and with liabilities small, the decline mainly reflects accumulated losses.

Net loss attributable to controlling shareholders totaled KRW 14 billion across the last four quarters, so an interpretation based on book value depends on whether losses continue. The dividend is effectively absent, so a valuation argument based on dividends does not hold.

The relationship between book value per share and the share price needs to be read together with changes in the equity base and whether trading resumes. Compared with past valuation bands, earnings-based multiples are not applicable while losses persist.

On a factual comparison, the share price sits low relative to book assets, but valuation interpretation remains limited until a recovery in results and resumption of trading are confirmed.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Transition pipeline

The company describes Nutracos Drinkable as forming a stable revenue flow, and the Gangnam Oppa platform adds finance and advertising income. On the device side, Aminogum Gel and Suneokos are both advancing through domestic approval.

Suneokos has completed TGA registration in Australia, which supports the case for an overseas distribution base.

Balance sheet capacity

Total liabilities were KRW 4.16 billion at the end of 2025 and the debt-to-equity ratio was 6.2%. Total equity of KRW 66.8 billion is all attributable to controlling shareholders, so debt burden is small. This is a relative strength in the balance sheet even as losses continue.

Narrowing quarterly losses

The operating loss narrowed from KRW 3 billion in Q1 2026 to KRW 204 million in Q3 2026. Net loss attributable to controlling shareholders also narrowed, from KRW 6 billion in Q4 2025 to KRW 1.04 billion in Q3 2026. The company expects turnaround to become visible as its business transition takes hold in 2026.

09

Bear factors

Continuing revenue decline

Quarterly revenue has declined for four consecutive quarters from Q4 2025 through Q3 2026. Q3 2026 revenue of KRW 553 million was down 72.5% year on year. The 58.1% revenue rise in 2025 has reversed in 2026, which is the main bearish point.

Persistent losses and cash outflow

The company recorded operating losses for four consecutive years from 2022 through 2025, with an operating margin of -84.3% in 2025. Operating cash flow was -KRW 11.3 billion in 2025, in contrast to a positive figure in 2024.

Net loss attributable to controlling shareholders reached KRW 30.2 billion in 2025, reversing from profit the year before.

Trading suspension and disclaimer of opinion

Trading has been suspended since February 9, 2026 due to a listing-eligibility substantive review trigger. The review of the first half of 2026 returned a disclaimer of opinion on both consolidated and standalone statements.

The company attributes the suspension to accumulated penalty points for late disclosures, partly from prior management.

10

Risk factors

Trading suspension and listing status

Whether trading resumes and whether the listing is maintained depends on the outcome of the substantive review. The company names business normalization and the resolution of costly legal disputes as key conditions for resuming trading.

The decision date has not been confirmed, so the length of the suspension and liquidity afterward remain uncertain.

Accounting and disclosure credibility

The review of the first half of 2026 resulted in a disclaimer of opinion on both consolidated and standalone statements. Accumulated penalty points for late disclosures led to the trading halt, and the company has named restoring disclosure credibility as a priority. The audit opinion in the 2026 annual report is the next checkpoint for this risk.

Governance and fundraising

Legal disputes over control and an extraordinary shareholder meeting continued, and in January 2026 a court injunction barring new share issuance led the company to withdraw a third-party share offering. The largest shareholder group held 15.45%. If legal disputes block fundraising plans, funding for business investment could be constrained.

11

What to watch next

  1. Schedule unconfirmed (date of the substantive review decision)

    Outcome of the listing-eligibility substantive review and whether trading resumes. The decision determines whether the company remains listed, which sets the context for interpreting operating metrics.

  2. By March 31, 2027 (deadline for the 2026 annual report)

    Full-year 2026 revenue, operating loss and the external auditor's opinion. Whether the disclaimer seen in the first-half review carries into the annual audit is the benchmark for restored disclosure credibility.

  3. Around late March 2027 (the 2025 annual preliminary results were disclosed on March 27, 2026)

    The timing of the 2026 annual preliminary results and how four consecutive quarters of revenue decline appear on a full-year basis. The key point is whether the narrowing quarterly operating loss carries into the full-year loss.

  4. Schedule unconfirmed

    The outcome of domestic approval for Aminogum Gel. Approval determines whether medical device revenue ramps up and whether the hospital channel produces results.

12

Overall view

InkredibleBuzz has been moving its business from luxury distribution toward healthcare and medical devices since a change in its largest shareholder in 2024.

Its disclosed results show an operating loss in each year from 2022 through 2025, and in 2025 the operating loss widened to KRW 6.08 billion even as revenue rose 58.1%, while net loss attributable to controlling shareholders reached KRW 30.2 billion.

In 2026, quarterly revenue declined for four consecutive quarters, but the operating loss narrowed to KRW 204 million in Q3 2026. On the balance sheet, the debt-to-equity ratio was 6.2% at the end of 2025, but total equity fell from KRW 96.8 billion at the end of 2024 to KRW 66.8 billion at the end of 2025.

Strengths include the stable revenue flow from Nutracos, approvals in progress for medical devices and Suneokos's registration in Australia. Weaknesses include the revenue decline, sustained losses, the trading suspension and the disclaimer of opinion for the first half of 2026.

The company has named business normalization and resolution of legal disputes as conditions for resuming trading. The next checkpoints are the substantive review decision, the full-year results and audit opinion in the 2026 annual report, and the outcome of Aminogum Gel approval.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. news.nate.com
  3. sedaily.com
  4. core.asiae.co.kr
  5. daily.hankooki.com
  6. newstomato.com
  7. m.news.nate.com
  8. dealsite.co.kr
  9. dailyinvest.kr
  10. datatooza.com
  11. kpinfo.kr
  12. digitaltoday.co.kr
  13. digitaltoday.co.kr
  14. news.nate.com
  15. m.news.nate.com
  16. digitaltoday.co.kr
  17. nicebizinfo.com
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis